2001
DOI: 10.1016/s1053-2498(00)00568-4
|View full text |Cite
|
Sign up to set email alerts
|

Monotherapy with anti-CD40 ligand antibody (IDEC 131) for non-human primate allograft heart transplantation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
12
0

Year Published

2006
2006
2019
2019

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 17 publications
(13 citation statements)
references
References 0 publications
1
12
0
Order By: Relevance
“…As previously reported in this experimental series (12,29) and with another reagent (15), early graft cellular infiltration is typical in the setting of CD154 blocking monotherapy with IDEC-131 ( Fig. 2A).…”
Section: Graft Cellular Infiltration Under Cd154 Blockadesupporting
confidence: 86%
“…As previously reported in this experimental series (12,29) and with another reagent (15), early graft cellular infiltration is typical in the setting of CD154 blocking monotherapy with IDEC-131 ( Fig. 2A).…”
Section: Graft Cellular Infiltration Under Cd154 Blockadesupporting
confidence: 86%
“…However, the use of one of this anti-CD154 mAb-hu5C8-in human renal transplantation elicited thrombotic side effects that were also observed lately in NHPs (66), and thus precluded continued clinical trials. Anti-CD40 mAbs were similarly tested in the same species and prolonged the survival of islet and kidney allografts; however, long-term acceptance and true tolerance were not observed (67,68,69).…”
Section: Monoclonal Antibody or Fusion Protein Therapymentioning
confidence: 99%
“…7, 23, 35 By using a directly comparable treatment regimen, here we show that both 5C8H1 and 2C10R4 significantly prolong cardiac allograft survival compared to historical IDEC-131 treated allografts. Additionally, 5C8H1 and 2C10R4 are each associated with improved control of pathogenic immunity, as demonstrated by reduced CAV severity scores during the second and third months of treatment and attenuation of alloAb development during treatment relative to IDEC-131, which is concordant with findings in several different NHP models using 5C8H1 or 2C10R4.…”
Section: Discussionmentioning
confidence: 68%